Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Current Opinion in Ophthalmology|April 16, 2010
Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic reviewChristine Schmucker, Christoph Ehlken, Lutz L Hansen, et al.
Plos One|August 11, 2012
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandardChristine Schmucker, Christoph Ehlken, Hansjuergen T Agostini, et al.
The British Journal of Ophthalmology|October 26, 2010
Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety reviewChristine Schmucker, Yoon K Loke, Christoph Ehlken, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|November 15, 2008
[Randomised controlled trials (RCTs)]Jürgen Windeler, Gerd Antes, Johann Behrens, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|August 12, 2009
Diagnostic accuracy of vision screening tests for the detection of amblyopia and its risk factors: a systematic reviewChristine Schmucker, Robert Grosselfinger, Rob Riemsma, et al.
BMC Ophthalmology|July 18, 2009
Effectiveness of screening preschool children for amblyopia: a systematic reviewChristine Schmucker, Robert Grosselfinger, Rob Riemsma, et al.
Ophthalmic Epidemiology|January 27, 2010
Effectiveness of early in comparison to late(r) treatment in children with amblyopia or its risk factors: a systematic reviewChristine Schmucker, Jos Kleijnen, Robert Grosselfinger, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|June 21, 2016
[Is the age of causality over?]Gerd Antes
Zeitschrift Fur Arztliche Fortbildung Und Qualitatssicherung|July 15, 2004
[The evidence base of clinical practice guidelines, health technology assessments and patient information as a basis for clinical decision-making]Gerd Antes
Zeitschrift Fur Arztliche Fortbildung Und Qualitatssicherung|December 2, 2006
[How much evidence is needed in the case of fatal diseases and when?]Gerd Antes
Pageof 17